This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Subscribe To Our Newsletter & Stay Updated